XNCR News
Archived Headlines
- Biotech Xencor postpones $75 million IPO 11/15/13
- Xencor increases shares offered and cuts IPO price to $7, deal size is still $75 million 11/14/13
- 12 US IPOs planned for the week of Nov 11 11/11/13
- Autoimmune biotech Xencor sets terms for $75 million IPO 11/04/13
- Autoimmune biotech Xencor files for a $69 million IPO 10/11/13
Anitbody biotech Alder BioPharmaceuticals files for a $115 million IPO
Alder BioPharmaceuticals, a biotech developing antibodies to treat migraines and arthritis, filed on Wednesday with the SEC to raise up to $115 million in an initial public offering. The Bothell, WA-based company, which was founded in 2002 and booked $19 million...read more
US IPO Recap: Hilton and eleven others set terms
Setting the stage for a potentially record-breaking week in the US IPO market, twelve companies set terms last week. The largest of these were Hilton Worldwide (HLT), the world's largest hotel chain, and ARAMARK (ARMK), the third-largest provider of food and...read more
Xencor prices IPO at $5.50, at lower revised share price
Xencor, a biotech developing antibodies for severe autoimmune/allergic diseases and cancer, raised $70 million by offering 12.7 million shares at $5.50. The company, which revised its terms yesterday, had originally filed to offer 5 million shares at $14 to $16...read more
Biotech Xencor increases shares and decreases its IPO price range after November postponement
Xencor, a biotech developing antibodies for severe autoimmune/allergic diseases and cancer, lowered the proposed deal size for its upcoming IPO on Monday. The Monrovia, CA-based company now plans to raise $70 million by offering 12.7 million shares at $5.50 per...read more